Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies

References

• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108–133. doi:10.1016/j.survophthal.2009.07.005
   PubMed Web of Science ®Google Scholar
• Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42(1):1–11. doi:10.1097/00004397-200201000-00003
   PubMedGoogle Scholar
• Lindstrom R. The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. Int Ophthalmol Clin. 2006;46(4):7–11. doi:10.1097/01.iio.0000212131.98760.a9
   Google Scholar
• Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. Aaps J. 2008;10(2):229–241. doi:10.1208/s12248-007-9006-3
   PubMed Web of Science ®Google Scholar
• Farah AE, Rosenberg F. Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. Br J Clin Pharmacol. 1980;10(Suppl 2):261S–278S. doi:10.1111/j.1365-2125.1980.tb01809.x
   Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981. doi:10.1155/2013/281981
   PubMedGoogle Scholar
• Chen H. Recent developments in ocular drug delivery. J Drug Target. 2015;23(7–8):597–604. doi:10.3109/1061186X.2015.1052073
   PubMed Web of Science ®Google Scholar
• Acuvail [package Insert]. Irvine, CA: Allergan, Inc.; 2014.
   Google Scholar
• Ilevro [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2014.
   Google Scholar
• Prolensa [package insert]. Tampa, FL: Bausch and Lomb Inc.; 2013.
   Google Scholar
• Voltaren [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2012.
   Google Scholar
• Acular [package insert]. Irvine, CA: Allergan, Inc.; 2012.
   Google Scholar
• Wilson DJ, Schutte SM, Abel SR. Comparing the efficacy of ophthalmic NSAIDs in common indications: a literature review to support cost-effective prescribing. Ann Pharmacother. 2015;49(6):727–734. doi:10.1177/1060028015574593
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Farah ME, Bottós JM, Bom Aggio F. Nonsteroidal anti-inflammatory drugs in the treatment of retinal diseases. Dev Ophthalmol. 2016;55:212–220.
   PubMedGoogle Scholar
• Seth A, Ghosh B, Raina UK, Gupta A, Arora S. Intravitreal diclofenac in the treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2016;47(2):149–155. doi:10.3928/23258160-20160126-08
   Web of Science ®Google Scholar
• Appiotti A, Gualdi L, Alberti M, Gualdi M. Comparative study of the analgesic efficacy of flurbiprofen and diclofenac in patients following excimer laser photorefractive keratectomy. Clin Ther. 1998;20(5):913–920.
   PubMed Web of Science ®Google Scholar
• Kim SK, Hong JP, Nam SM, Stulting RD, Seo KY. Analgesic effect of preoperative topical nonsteroidal antiinflammatory drugs on postoperative pain after laser-assisted subepithelial keratectomy. J Cataract Refract Surg. 2015;41(4):749–755. doi:10.1016/j.jcrs.2014.06.041
   Web of Science ®Google Scholar
• Mohammadpour M, Jabbarvand M, Nikdel M, Adelpour M, Karimi N. Effect of preemptive topical diclofenac on postoperative pain relief after photorefractive keratectomy. J Cataract Refract Surg. 2011;37(4):633–637. doi:10.1016/j.jcrs.2010.10.040
   Web of Science ®Google Scholar
• Sher NA, Frantz JM, Talley A, et al. Topical diclofenac in the treatment of ocular pain after excimer photorefractive keratectomy. Refract Corneal Surg. 1993;9(6):425–436.
   Google Scholar
• Solomon KD, Donnenfeld ED, Raizman M, et al; On behalf of Ketorolac Reformulation Study Groups 1 and 2. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg. 2004;30(8):1653–1660. doi:10.1016/S0886-3350(03)00497-8.
   PubMed Web of Science ®Google Scholar
• Tutton MK, Cherry PM, Raj PS, Fsadni MG. Efficacy and safety of topical diclofenac in reducing ocular pain after excimer photorefractive keratectomy. J Cataract Refract Surg. 1996;22(5):536–541. doi:10.1016/S0886-3350(96)80005-8
   Web of Science ®Google Scholar
• Weinstock VM, Weinstock DJ, Weinstock SJ. Diclofenac and ketorolac in the treatment of pain after photorefractive keratectomy. J Refract Surg. 1996;12(7):792–794.
   PubMed Web of Science ®Google Scholar
• Schechter BA, Trattler W. Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. Adv Ther. 2010;27(10):756–761. doi:10.1007/s12325-010-0066-x
   Web of Science ®Google Scholar
• Mohammadpour M, Heidari Z, Molani R. Comparison between diclofenac and ketorolac ophthalmic drops for pain management after photorefractive keratectomy: a randomized clinical study. Eye Contact Lens. 2019;45(2):137–140. doi:10.1097/ICL.0000000000000524
   PubMed Web of Science ®Google Scholar
• Hong JP, Nam SM, Im CY, et al. Comparison of analgesic effect of preoperative topical diclofenac and ketorolac on postoperative pain after photorefractive keratectomy. J Cataract Refract Surg. 2014;40(10):1689–1696. doi:10.1016/j.jcrs.2014.05.029
   Web of Science ®Google Scholar
• Li S, Hu A, Wang W, Ding X, Lu L, Jablonski MM. Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis. PLoS One. 2017;12(10):e0184998. doi:10.1371/journal.pone.0184998
   Web of Science ®Google Scholar
• Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993;38 Suppl:133–140. doi:10.1016/0039-6257(93)90037-8
   Web of Science ®Google Scholar
• Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther. 1998;14(2):137–145. doi:10.1089/jop.1998.14.229
   PubMed Web of Science ®Google Scholar
• Swamy BN, Chilov M, McClellan K, Petsoglou C. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiol. 2007;14(5):311–319. doi:10.1080/09286580701344399
   PubMed Web of Science ®Google Scholar
• Sawa M, Masuda K, Usui M, Komemushi S. Efficacy of 0.1% bromfenac sodium ophthalmic solution for ocular surface inflammation: a double-masked controlled trial. Folia Ophthalmol Jpn. 1997;48(5):717–724.
   Google Scholar
• Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol. 1997;45(3):177–180.
   PubMedGoogle Scholar
• Kosrirukvongs P, Luengchaichawange C. Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis. J Med Assoc Thai. 2004;87:190–197.
   Google Scholar
• Chen J, Dong F, Chen W, et al. Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial. Chin Med J (Engl). 2014;127(13):2407–2412.
   Web of Science ®Google Scholar
• Baklayan GA, Muñoz M. The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model. Clin Ophthalmol. 2014;8:1717–1724. doi:10.2147/OPTH.S66638
   Google Scholar
• Malhotra M, Majumdar DK. Permeation through cornea. Indian J Exp Biol. 2001;39(1):11–24.
   PubMedGoogle Scholar
• Lawrence MS, Miller JW. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004;44(3):53–61. doi:10.1097/00004397-200404430-00008
   Google Scholar
• Bromsite [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2016.
   Google Scholar
• Si EC, Bowman LM, Hosseini K. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. J Ocul Pharmacol Ther. 2011;27(1):61–66. doi:10.1089/jop.2010.0103
   PubMed Web of Science ®Google Scholar
• Walsh DA, Moran HW, Shamblee DA, et al. Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J Med Chem. 1984;27(11):1379–1388. doi:10.1021/jm00377a001
   Web of Science ®Google Scholar
• Sancilio LF, Nolan JC, Wagner LE, Ward JW. The analgesic and antiinflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung. 1987;37(5):513–519.
   Web of Science ®Google Scholar
• Ruiz J, López M, Milà J, Lozoya E, Lozano JJ, Pouplana R. QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues. J Comput Aided Mol Des. 1993;7(2):183–198. doi:10.1007/BF00126444
   Web of Science ®Google Scholar
• Kida T, Kozai S, Takahashi H, Isaka M, Tokushige H, Sakamoto T. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014;9(5):e96481. doi:10.1371/journal.pone.0096481
   PubMed Web of Science ®Google Scholar
• Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33(9):1539–1545. doi:10.1016/j.jcrs.2007.05.015
   PubMed Web of Science ®Google Scholar
• Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22(6):1133–1140. doi:10.1185/030079906X112471
   PubMed Web of Science ®Google Scholar
• Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392–398. doi:10.1089/jop.2007.0082
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Cockrum PC, Justice A, Jasek MC. In vivo pharmacokinetics of bromfenac ophthalmic solution 0.075%, Bromfenac ophthalmic solution 0.07%, and nepafenac/amfenac ophthalmic suspension 0.3% in rabbits. Ophthalmol Ther. 2018;7(1):157–165. doi:10.1007/s40123-018-0130-1
   Web of Science ®Google Scholar
• Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433–439. doi:10.1089/jop.2009.0026
   Web of Science ®Google Scholar
• Hosseini K, Walters T, DaVanzo R, Lindstrom RL. A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects. Clin Ophthalmol. 2016;10:2311–2317. doi:10.2147/OPTH.S120428
   PubMed Web of Science ®Google Scholar
• Miyake K, Ogawa T, Tajika T, Gow JA, McNamara TR. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. J Ocul Pharmacol Ther. 2008;24(6):573–578. doi:10.1089/jop.2007.0132
   Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Adv Ther. 2009;26(6):645–650. doi:10.1007/s12325-009-0042-5
   Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Adv Ther. 2011;28:1089–1095. doi:10.1007/s12325-011-0080-7
   PubMed Web of Science ®Google Scholar
• Walters TR, Smyth-Medina RJ, Cockrum PC. An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations. Clin Ophthalmol. 2018;12:943–947. doi:10.2147/OPTH.S170540
   Web of Science ®Google Scholar
• Russo A, Morescalchi F, Vezzoli S, et al. Reduction of vitreous prostaglandin e2 levels after topical administration of indomethacin 0.5%, bromfenac 0.09%, and nepafenac 0.1. Retina. 2016;36(6):1127–1131. doi:10.1097/IAE.0000000000000860
   Web of Science ®Google Scholar
• Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009;29(9):1310–1313. doi:10.1097/IAE.0b013e3181b094e6
   PubMed Web of Science ®Google Scholar
• Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10(14):2379–2385. doi:10.1517/14656560903092197
   PubMed Web of Science ®Google Scholar
• Hoy SM. Bromfenac ophthalmic solution 0.07%: a review of its use after cataract surgery. Clin Drug Investig. 2015;35(8):525–529. doi:10.1007/s40261-015-0309-3
   Web of Science ®Google Scholar
• Rajpal RK, Ross B, Rajpal SD, Hoang K. Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Prefer Adherence. 2014;8:925–931. doi:10.2147/PPA.S46667
   PubMed Web of Science ®Google Scholar
• Sheppard JD. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review. Clin Ophthalmol. 2016;10:2099–2111. doi:10.2147/OPTH.S86971
   Web of Science ®Google Scholar
• Li SM, Zhan S, Li SY, et al. Laser-assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia. Cochrane Database Syst Rev. 2016;2:CD009799. doi:10.1002/14651858.CD004158.pub3
   Web of Science ®Google Scholar
• Kuryan J, Cheema A, Chuck RS. Laser-assisted subepithelial keratectomy (LASEK) versus laser-assisted in-situ keratomileusis (LASIK) for correcting myopia. Cochrane Database Syst Rev. 2017;2:CD011080.
   Google Scholar
• Cleaveland NA, De Mann DW, Carlson NE, Keil ML. Efficacy and perioperative timing of bromfenac in the management of ocular discomfort after femtosecond laser-assisted laser in situ keratomileusis. J Cataract Refract Surg. 2017;43(2):183–188. doi:10.1016/j.jcrs.2016.11.042
   PubMed Web of Science ®Google Scholar
• Chen S, Jiang Y, Yu C, Li Y. Comparison of clinical effects of bromfenac sodium ophthalmic solution 0.1% versus glucocorticoids for post-LASEK usage. Chin J Ophthalmol. 2015;51(1):45–50.
   Google Scholar
• Dong Y, Zhang Y, Xia Y, Wang B, Chen Y. Efficacy observation of 0.1% bromfenac sodium eye drops on relieving the post-LASEK irritative symptoms. Chin J Ophthalmol. 2015;51(1):51–54.
   Google Scholar
• Durrie DS, Kennard MG, Boghossian AJ. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral Photorefractive Keratectomy (PRK). Adv Ther. 2007;24(6):1278–1285. doi:10.1007/BF02877774
   Web of Science ®Google Scholar
• Sher NA, Golben MR, Bond W, Trattler WB, Tauber S, Voirin TG. Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK. J Refract Surg. 2009;25(2):214–220.
   Web of Science ®Google Scholar
• Wang XJ, Wong SH, Givergis R, Chynn EW. Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK. Clin Ophthalmol. 2011;5:1451–1457.
   Google Scholar
• Xu Y, Zhao X, Zhang FJ, et al. The clinical efficacy of 0.1% bromfenac sodium hydrate ophthalmic solution after excimer laser in situ keratomileusis. Chin J Ophthalmol. 2013;49(4):320–326.
   Google Scholar
• Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017;27(3):326–330. doi:10.5301/ejo.5000888
   PubMed Web of Science ®Google Scholar
• Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1801–1806. doi:10.1007/s00417-013-2309-4
   PubMed Web of Science ®Google Scholar
• Shimura M, Yasuda K. Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. Br J Ophthalmol. 2015;99(2):215–219. doi:10.1136/bjophthalmol-2013-304720
   PubMed Web of Science ®Google Scholar
• Grant CA. Combination therapy: lucentis (ranibizumab injection) and Xibrom (bromfenac ophthalmic solution) 0.09% in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:563. doi:10.1167/iovs.07-0624
   Web of Science ®Google Scholar
• Flaxel C, Schain MB, Hamon SC, Francis PJ. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina. 2012;32(3):417–423. doi:10.1097/IAE.0b013e318229b0af
   PubMed Web of Science ®Google Scholar
• Gomi F, Sawa M, Tsujikawa M, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012;32(9):1804–1810. doi:10.1097/IAE.0b013e31825be87f
   PubMed Web of Science ®Google Scholar
• Wygledowska-Promienska D, Piotrowska-Gwóźdź A, Piotrowska-Seweryn A, Mazur-Piotrowska G, Rokicki W. Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study. Med Sci Monit. 2014;20:1168–1175. doi:10.12659/MSM.890197
   PubMed Web of Science ®Google Scholar
• Wygledowska-Promienska D, Piotrowska-Gwóźdź A, Piotrowska-Seweryn A, Mazur-Piotrowska G. Combination of aflibercept and bromfenac therapy in age-related macular degeneration: a pilot study aflibercept and bromfenac in AMD. Med Sci Monit. 2015;21:3906–3912. doi:10.12659/MSM.895977
   Web of Science ®Google Scholar
• Georgakopoulos CD, Tsapardoni F, Makri OE. Effect of bromfenac on pain related to intravitreal injections: a randomized crossover study. Retina. 2017;37(2):388–395. doi:10.1097/IAE.0000000000001137
   PubMed Web of Science ®Google Scholar
• Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol. 2004;48(6):587–590. doi:10.1007/s10384-004-0127-2
   PubMed Web of Science ®Google Scholar
• Fujishima H, Fukagawa K, Takano Y, et al. Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25(3):265–270. doi:10.1089/jop.2008.0121
   PubMed Web of Science ®Google Scholar
• Uchio E, Itoh Y, Kadonosono K. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica. 2007;221(3):153–158. doi:10.1159/000099294
   PubMed Web of Science ®Google Scholar
• Fujishima H, Fuseya M, Ogata M, Murat D. Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease. Asis Pac J Ophthalmol (Phila). 2015;4(1):9–13. doi:10.1097/APO.0000000000000032
   Google Scholar
• Usui M, Masuda K. Effect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitis. Jpn Rev Clin Ophthalmol. 1997;91(5):739–744.
   Google Scholar
• Donnenfeld ED, Holland EJ, Durrie DS, Raizman MB. Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. Adv Ther. 2007;24(4):852–862. doi:10.1007/BF02849978
   Web of Science ®Google Scholar
• Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20–68. doi:10.1016/j.preteyeres.2017.10.006
   PubMed Web of Science ®Google Scholar
• Pournaras C, Tsacopoulos M, Chapuis P. Studies on the role of prostaglandins in the regulation of retinal blood flow. Exp Eye Res. 1978;26(6):687–697. doi:10.1016/0014-4835(78)90103-3
   Web of Science ®Google Scholar
• Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol. 2011;21(Suppl 6):S10–S19. doi:10.5301/EJO.2010.6050
   PubMed Web of Science ®Google Scholar
• Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs. 2010;70(16):2171–2200. doi:10.2165/11538130-000000000-00000
   Web of Science ®Google Scholar
• Wolfensberger TJ, Gregor ZJ. Macular edema–rationale for therapy. Dev Ophthalmol. 2010;47:49–58.
   PubMedGoogle Scholar
• Zhang R, Liu Z, Zhang H, Zhang Y, Lin D. The COX-2-selective antagonist (NS-398) inhibits choroidal neovascularization and subretinal fibrosis. PLoS One. 2016;11(1):e0146808. doi:10.1371/journal.pone.0146808
   PubMed Web of Science ®Google Scholar
• Sahoo S, Barua A, Myint KT, Haq A, Abas AB, Nair NS. Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema. Cochrane Database Syst Rev. 2015;(2):CD010009.
   Web of Science ®Google Scholar
• Flaxman SR, Bourne RRA, Resnikoff S, et al; On behalf of the Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234. doi:10.1016/S2214-109X(17)30393-5.
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern^® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. Available from https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015. Accessed March 26, 2018.
   Google Scholar
• Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond). 2011;25(2):127–139. doi:10.1038/eye.2010.196
   PubMed Web of Science ®Google Scholar
• Segal O, Segal-Trivitz Y, Nemet AY, Cohen P, Geffen N, Mimouni M. Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. 2016;94(2):203–204. doi:10.1111/aos.2016.94.issue-2
   PubMed Web of Science ®Google Scholar
• Rifkin L, Schaal S. Shortening ocular pain duration following intravitreal injections. Eur J Ophthalmol. 2012;22(6):1008–1012. doi:10.5301/ejo.5000147
   PubMed Web of Science ®Google Scholar
• Ulrich JN. Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial. Retina. 2014;34(3):509–511. doi:10.1097/IAE.0b013e3182a0e611
   PubMed Web of Science ®Google Scholar
• American Optometric Association. Care of the patient with ocular surface disorders. Optometric Clinical Practice Guideline. St. Louis, MO; 2010.
   Google Scholar
• American Optometric Association. Care of the patient with anterior uveitis. Optometric Clinical Practice Guideline. St Louis, MO; 2010.
   Google Scholar
• Nebbioso M, Del Regno P, Gharbiya M, Sacchetti M, Plateroti R, Lambiase A. Analysis of the pathogenic factors and management of dry eye in ocular surface disorders. Int J Mol Sci. 2017;18(8):E1764. doi:10.3390/ijms18081764
   Web of Science ®Google Scholar
• Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993;38 Suppl:141–148. doi:10.1016/0039-6257(93)90038-9
   Web of Science ®Google Scholar
• Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand. 2003;81(4):378–382. doi:10.1034/j.1600-0420.2003.00079.x
   PubMedGoogle Scholar
• Laibovitz RA, Koester J, Schaich L, Reaves TA. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther. 1995;11(3):361–368. doi:10.1089/jop.1995.11.361
   PubMed Web of Science ®Google Scholar
• Sand BB, Krogh E. Topical indometacin, a prostaglandin inhibitor, in acute anterior uveitis. A controlled clinical trial of non-steroid versus steroid anti-inflammatory treatment. Acta Ophthalmol (Copenh). 1991;69(2):145–148. doi:10.1111/j.1755-3768.1991.tb02703.x
   Google Scholar
• Congdon NG, Schein OD, von Kulajta P, Lubomski LH, Gilbert D, Katz J. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2001;27(4):622–631. doi:10.1016/S0886-3350(01)00801-X
   Web of Science ®Google Scholar
• Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002;25(4):233–250. doi:10.2165/00002018-200225040-00002
   PubMed Web of Science ®Google Scholar